T. Rowe Price Associates Portfolio holdings
T. Rowe Price Associates, Inc., founded in 1937 by Thomas Rowe Price, Jr., is a globally recognized investment management firm headquartered in Baltimore, Maryland, known for its disciplined, research-driven approach to active investing. The company manages hundreds of billions in assets, offering a wide range of mutual funds, retirement plans, and advisory services tailored to individual investors, institutions, and financial intermediaries. Emphasizing long-term growth and a conservative investment philosophy, T. Rowe Price has built a strong reputation for its equity and fixed-income funds, often focusing on fundamental analysis to identify undervalued opportunities. Still publicly traded and independent, it remains a trusted name in the industry, balancing tradition with innovation to meet evolving client needs.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
AGN
Allergan Inc
AGN
|
+$1.3B |
| 2 |
American Airlines Group
AAL
|
+$853M |
| 3 |
Intuitive Surgical
ISRG
|
+$816M |
| 4 |
Morgan Stanley
MS
|
+$681M |
| 5 |
Wynn Resorts
WYNN
|
+$622M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Procter & Gamble
PG
|
+$1.4B |
| 2 |
eBay
EBAY
|
+$763M |
| 3 |
DISCK
Discovery, Inc. Series C Common Stock
DISCK
|
+$760M |
| 4 |
Broadcom
AVGO
|
+$757M |
| 5 |
US Bancorp
USB
|
+$686M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 16.64% |
| 2 | Consumer Discretionary | 13.46% |
| 3 | Financials | 12.79% |
| 4 | Industrials | 12.13% |
| 5 | Technology | 9.46% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1601
Carlisle Companies
CSL
$15.2B
| $1.67M | ﹤0.01% |
19,235
-1,476
| -7% | -$123K |
|
1602
Brown-Forman Class A
BF.A
$13B
| $1.66M | ﹤0.01% |
45,000
| – | – |
|
|
TUP
1603
DELISTED
Tupperware Brands Corporation
TUP
| $1.66M | ﹤0.01% |
19,820
+3,200
| +19% | +$269K |
|
|
UTEK
1604
DELISTED
Ultratech Inc.
UTEK
| $1.65M | ﹤0.01% |
74,300
-29,400
| -28% | -$738K |
|
1605
Bio-Techne
TECH
$11.3B
| $1.65M | ﹤0.01% |
71,072
+5,252
| +8% | +$116K |
|
1606
Equity Lifestyle Properties
ELS
$12.4B
| $1.64M | ﹤0.01% |
74,080
-3,000
| -4% | -$64K |
|
|
YUME
1607
DELISTED
YuMe, Inc.
YUME
| $1.63M | ﹤0.01% |
+277,029
| New | +$1.68M |
|
|
BRLI
1608
DELISTED
BIO-REFERENCE LABS INC-NEW-
BRLI
| $1.63M | ﹤0.01% |
54,000
-59,700
| -53% | -$1.65M |
|
|
GPOR
1609
DELISTED
Gulfport Energy Corp.
GPOR
| $1.63M | ﹤0.01% |
25,873
+2,102
| +9% | +$141K |
|
|
CIE
1610
DELISTED
Cobalt International Energy, Inc
CIE
| $1.62M | ﹤0.01% |
5,893
| – | – |
|
1611
iShares MSCI Japan ETF
EWJ
$23.2B
| $1.61M | ﹤0.01% |
33,375
+8,325
| +33% | +$380K |
|
1612
Huntsman Corp
HUN
$1.78B
| $1.6M | ﹤0.01% |
57,100
+3,400
| +6% | +$89K |
|
|
BRCD
1613
DELISTED
Brocade Communications Systems, Inc. NEW
BRCD
| $1.59M | ﹤0.01% |
173,055
+11,969
| +7% | +$110K |
|
|
BRFS
1614
DELISTED
BRF SA
BRFS
| $1.59M | ﹤0.01% |
65,300
-8,900
| -12% | -$201K |
|
|
RPXC
1615
DELISTED
RPX Corporation
RPXC
| $1.57M | ﹤0.01% |
88,200
-128,450
| -59% | -$2.13M |
|
1616
SEI Investments
SEIC
$12.7B
| $1.56M | ﹤0.01% |
47,696
+3,045
| +7% | +$98.1K |
|
|
ITC
1617
DELISTED
ITC HOLDINGS CORP
ITC
| $1.56M | ﹤0.01% |
42,700
+3,700
| +9% | +$137K |
|
|
IMI
1618
DELISTED
Intermolecular, Inc.
IMI
| $1.54M | ﹤0.01% |
663,000
| – | – |
|
|
PPLI
1619
People Inc
PPLI
$3.02B
| $1.54M | ﹤0.01% |
124,778
| – | – |
|
1620
SITE Centers
SITC
$156M
| $1.53M | ﹤0.01% |
67,521
| – | – |
|
1621
Manulife Financial
MFC
$72.6B
| $1.52M | ﹤0.01% |
76,300
+30,800
| +68% | +$582K |
|
|
FWLT
1622
DELISTED
FOSTER WHEELER AG (SWITZERLAND)
FWLT
| $1.51M | ﹤0.01% |
44,400
+2,200
| +5% | +$74.4K |
|
|
IM
1623
DELISTED
Ingram Micro
IM
| $1.51M | ﹤0.01% |
51,582
+496
| +1% | +$13.9K |
|
|
LPT
1624
DELISTED
Liberty Property Trust
LPT
| $1.49M | ﹤0.01% |
39,333
| – | – |
|
|
UFS
1625
DELISTED
DOMTAR CORPORATION (New)
UFS
| $1.49M | ﹤0.01% |
34,782
| – | – |
|
Similar funds
T. Rowe Price Associates's Q2 2014 Portfolio in Review
As of Q2 2014, T. Rowe Price Associates held 2,596 positions worth $463B, up 3.9% from $445B the previous quarter. Its ten largest holdings account for 12% of the portfolio.
T. Rowe Price Associates's Q2 2014 filing shows 97 new, 1,091 increased, 793 reduced and 67 closed positions. Its largest new stake was Teva Pharmaceuticals: 4,638,481 shares worth $243M. The largest sale was Procter & Gamble, an estimated $1.4B.
By sector, the portfolio is most concentrated in Healthcare at 17% of assets, up from 16% a quarter earlier, followed by Consumer Discretionary and Financials.
- T. Rowe Price Associates's largest Q2 2014 buy was Teva Pharmaceuticals: 4,638,481 shares worth $243M.
- T. Rowe Price Associates added most to Allergan Inc in Q2 2014, an estimated $1.3B increase.
- T. Rowe Price Associates's biggest Q2 2014 reduction was Procter & Gamble, cutting an estimated $1.4B.
- T. Rowe Price Associates fully exited Santander in Q2 2014, selling an estimated $134M.
- T. Rowe Price Associates's ten largest holdings make up 12% of its $463B portfolio in Q2 2014.
- T. Rowe Price Associates opened 97 new positions and closed 67 in Q2 2014.
- T. Rowe Price Associates's portfolio value rose 3.9% quarter-over-quarter to $463B.
Based on T. Rowe Price Associates's 13F filing for Q2 2014, filed 14 Aug 2014.